Literature DB >> 2477248

Human immunodeficiency virus reverse transcriptase expressed in transformed yeast cells. Biochemical properties and interactions with bovine tRNALys.

M L Sallafranque-Andreola1, D Robert, P J Barr, M Fournier, S Litvak, L Sarih-Cottin, L Tarrago-Litvak.   

Abstract

Human immunodeficiency virus (HIV) reverse transcriptase has been purified from yeast transformed by an autoreplicating plasmid containing the retroviral DNA polymerase gene. The previously described purification procedure for the yeast-expressed reverse transcriptase [Barr, P.J., Power, M.D., Chun Ting Lee-Ng, Gibson, H. & Luciw, P. (1987) Bio/Technology 5, 486-489] has been substantially modified, leading to an increased yield and a higher degree of purity. Several biochemical properties of the enzyme are described (template specificity, effect of DNA synthesis inhibitors); interestingly, HIV reverse transcriptase is highly resistant to N-ethylmaleimide. A complex between the human retroviral enzyme and the bovine tRNALys was shown, using a direct approach, by glycerol gradient centrifugation, as well as by the protective and specific effect of the tRNALys against enzyme inactivation by thermal denaturation and trypsin digestion. A competitive type of inhibition of HIV reverse transcriptase by tRNALys, but not by tRNAVal, is observed when viral RNA or activated DNA are used as templates.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477248     DOI: 10.1111/j.1432-1033.1989.tb15028.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  20 in total

1.  Initiation of HIV-2 reverse transcription: a secondary structure model of the RNA-tRNA(Lys3) duplex.

Authors:  F Freund; F Boulmé; S Litvak; L Tarrago-Litvak
Journal:  Nucleic Acids Res       Date:  2001-07-01       Impact factor: 16.971

2.  Purification and characterization of recombinant equine infectious anemia virus reverse transcriptase.

Authors:  S F Le Grice; M Panin; R C Kalayjian; N J Richter; G Keith; J L Darlix; S L Payne
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

3.  Stimulation of the human RAD51 nucleofilament restricts HIV-1 integration in vitro and in infected cells.

Authors:  O Cosnefroy; A Tocco; P Lesbats; S Thierry; C Calmels; T Wiktorowicz; S Reigadas; Y Kwon; A De Cian; S Desfarges; P Bonot; J San Filippo; S Litvak; E Le Cam; A Rethwilm; H Fleury; P P Connell; P Sung; O Delelis; M L Andréola; V Parissi
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

4.  Mutated primer binding sites interacting with different tRNAs allow efficient murine leukemia virus replication.

Authors:  A H Lund; M Duch; J Lovmand; P Jørgensen; F S Pedersen
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

Review 5.  Primer tRNAs for reverse transcription.

Authors:  J Mak; L Kleiman
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  Functional interactions of human immunodeficiency virus type 1 integrase with human and yeast HSP60.

Authors:  V Parissi; C Calmels; V R De Soultrait; A Caumont; M Fournier; S Chaignepain; S Litvak
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Replication of avian leukosis viruses with mutations at the primer binding site: use of alternative tRNAs as primers.

Authors:  J M Whitcomb; B A Ortiz-Conde; S H Hughes
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 can use different tRNAs as primers for reverse transcription but selectively maintains a primer binding site complementary to tRNA(3Lys).

Authors:  J K Wakefield; A G Wolf; C D Morrow
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Identification of tRNAs incorporated into wild-type and mutant human immunodeficiency virus type 1.

Authors:  M Jiang; J Mak; A Ladha; E Cohen; M Klein; B Rovinski; L Kleiman
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  Secondary structure of the HIV-2 leader RNA comprising the tRNA-primer binding site.

Authors:  B Berkhout; I Schoneveld
Journal:  Nucleic Acids Res       Date:  1993-03-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.